CMV Glycoprotein B Vaccine in Allograft Recipients
Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Patients who receive transplants are at increased risk of developing serious cytomegalovirus
(CMV) infections because they have a decreased immune system. The purpose of this study is to
evaluate the safety and immune response of a CMV vaccine in patients (18 years old and older)
who are awaiting a transplant. Following immunization with vaccine or placebo (inactive
substance), patients will be followed for the development of immune responses to CMV and for
evidence of CMV infection following transplantation. One hundred forty eligible patients will
receive 3 injections of the CMV gB vaccine or 3 doses of placebo during 5 visits.
Participants will participate in the study for approximately 7 months (if they do not undergo
a transplant) or 10 months (if they undergo a transplant).
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)